多药耐药基因1的C3435T、T129C多态性与儿童难治性癫痫的相关性

目的探讨多药耐药基因1(MDR1)C3435T、T129C多态性与儿童难治性癫痫之间的相关性。方法采用PCR-RFLP方法检测260例儿童,包括难治性癫痫患儿(难治组)60例、疗效良好的癫痫患儿(易治组)100例及健康儿童(对照组)100例的MDR1基因C3435T、T129C位点多态性,比较三组基因型分布和等位基因频率的差异。结果难治组、易治组与对照组的C3435T位点基因型(TT、TC、CC)分布以及等位基因(T和C)频率差异无统计学意义(P均0.05)。三组T129C位点基因型(TT、TC、CC)分布以及等位基因(T和C)频率差异有统计学意义(P均0.05);其中难治组TC基因型以及等位基因C的比例均较高。结论 MDR1基因T129C多态性可能与儿童难治性癫痫存在相关性。     

多药耐药基因C3435T多态性与儿童急性淋巴细胞白血病发生的meta分析

目的探讨多药耐药基因(MDR1)C3435T多态性与儿童急性淋巴细胞白血病(ALL)发生的关系。方法在万方数据库、中国全文期刊数据库、维普数据库和Pubmed数据库中检索MDR1 C3435T多态性与儿童ALL发生的相关文献,并应用RevMan 5.0软件对符合入选标准的文献进行异质性检验和效应值合并,同时进行敏感性分析和偏倚评估。结果纳入符合条件的相关文献6篇,共计ALL儿童1157例,对照儿童1189例。MDR1 CT、TT、CT+TT与儿童ALL的合并OR(95%CI)分别为1.05(0.86~1.30,Z=0.51,P=0.61),1.49(0.97~2.28,Z=1.84,P=0.07),1.19(0.98~1.44,Z=1.76,P=0.08)。各研究的敏感性分析较稳定且无发表偏倚。结论 MDR1 C3435T多态性与儿童ALL的发生无关。     

多药耐药基因C3435T多态性与儿童难治性癫癎耐药的Meta分析

目的探讨多药耐药基因(MDR1)C3435T多态性与儿童难治性癫癎耐药的关系。方法利用计算机在万方数据库、中国知网数据库、维普数据库和PubMed数据库中检索MDR1 C3435T多态性与儿童难治性癫癎耐药发生的文献,并应用RevMan 5.0软件对符合入选标准的文献进行异质性检验和效应值合并,同时进行敏感性分析和偏倚评估。结果纳入符合条件的相关文献5篇,共计难治性癫癎药物耐药组367例,药物敏感组488例。MDR1 CT、TT、CT+TT与儿童难治性癫癎耐药的合并OR值(95%CI)分别为0.89(0.65～1.23)、0.94(0.56～1.57)、0.92(0.64～1.32),Z=0.69、0.25、0.46,P=0.49、0.80、0.64。各研究的敏感性分析较稳定且无发表偏倚。结论 MDR1 C3435T多态性与儿童难治性癫癎耐药的发生无关。     

白细胞介素-8-251A/T和781C/T基因多态性与呼吸道合胞病毒毛细支气管炎的相关性

目的 探讨白细胞介素-8(IL-8)-251A/T和781C/T基因多态性与呼吸道合胞病毒(RSV)毛细支气管炎易感性的关系.方法 应用聚合酶链反应-限制性酶切片段长度多态性技术检测150例RSV毛细支气管炎患儿和120例健康对照儿童血IL-8-251A/T和781C/T的单核苷酸多态性(SNP),分析其基因型、等位基因型的分布,并对2个SNP位点进行连锁和单体型分析.结果 1.病例组和健康对照组均发现IL-8-251A/T位点基因多态性,均可见AA、AT和TT 3种基因型;其中病例组AA、AT、TT基因型频率分别为12.0%、56.7%、31.3%,A、T等位基因频率分别为40.3%、59.7%;健康对照组AA、AT、TT基因型频率分别为7.5%、54.2%、38.3%,A、T等位基因频率分别为34.6%、65.4%;病例组IL-8-251A/T基因型及等位基因频率与健康对照组比较,差异均无统计学意义(x2=2.373,1.875 P0.05).2.病例组和健康对照组均发现IL-8 781C/T位点基因多态性,均可见CC、CT、TT3种基因型;其中病例组CC、CT、TT基因型频率分别为38.7%、40.7%、20.6%,C、T等位基因频率分别为59.0%、41.0%;健康对照组CC、CT、TT基因型频率分别为40.8%、41.7%、17.5%,C、T等位基因频率分别为61.7%、38.3%,二组基因型及等位基因频率比较,差异均无统计学意义(x2=0.442,0.396 P0.05).3.IL-8-251A和781C是连锁的(D'=0.348±0.019,r2=0.114 P<0.05).4.病例组AC单体型频率显著增加(x2=9.047 P<0.05).结论 IL-8-251A和781C形成的AC单体型与RSV毛细支气管炎易感性相关,即部分RSV毛细支气管炎的易感基因可能存在于含有AC单体型的基因片段或与该段基因紧密连锁.     

MTHFR C677T基因多态性与儿童法洛四联症相关性的meta分析

目的探讨5,10-亚甲基四氢叶酸还原酶(MTHFR)基因多态性(C677T)与儿童法洛四联症的相关性。方法检索Pub Med、中国知网、万方和维普数据库,收集2017年7月以前发表的MTHFR基因多态性(C677T)与儿童法洛四联症病例的对照研究文献,根据纳入和排除标准,剔除不符合要求的文献,行Hardy-Weinberg遗传平衡检验后进行meta分析,并采用序贯试验分析(TSA)方法对结果进行检验。结果共有7篇文献纳入分析,包括1 222例法洛四联症患儿和1 443例对照儿童。Meta分析结果显示,MTHFR基因多态性(C 677 T)位点等位基因模型(T对C)合并后的总OR值为1.63,95%CI:1.41～1.88;显性基因模型(TT+TC对CC)合并后的总OR值为1.67,95%CI:1.34～2.10;隐性基因模型(TT对TC+CC)合并后的总OR值为2.08,95%CI:1.64～2.63;共显性杂合子基因模型(TC对CC)合并后的总OR值为1.36,95%CI:1.07～1.74;共显性纯合子基因模型(TT对CC)合并后的总OR值为2.56,95%CI:1.92～3.41。结论 MTHFRC 677 T基因多态性位点可增加法洛四联症风险。     

儿童难治性癫(癎)MDR1基因多态性研究

目的 探讨儿童难治性癫(癎)的诊断问题及汉族儿童难治性癫(癎)MDR1基因单核苷酸多态性C3435T与癫(癎)耐药的相关性.方法 采用回顾性及前瞻性分析方法对400例癫(癎)儿童进行随访,自定儿童难治性癫(癎)(RE)诊断标准,分析其中难治性癫(癎)类型、用药种类、用药时间、药物调整时间及疗效;根据对抗癫(癎)药物的反应将儿童癫(癎)患者分为难治组、控制组,健康儿童作为正常对照组;提取132例患儿(难治组70例,控制组62例)及健康62例儿童外周血DNA,以PCR扩增,DNA直接测序法检测MDR基因C3435T的单核苷酸多态性;应用病例对照研究,分析基因多态性在癫(癎)患者中的分布特点及其与癫(癎)耐药的相关性.结果 400例癫(癎)患儿中难治性癫(癎)83例(20.8%),65例(78.3%)在6个月内完成至少2种药物调整,目前仍有42例(50.6%)同时使用3种及以上药物治疗,其中6例(7.2%)同时使用4种抗癫(癎)药物.83例难治性癫(癎)患者用药有效40例(48.2%),显效6例(7.2%);无效37例(44.6%),其中25例(67.6%)有不同程度的减轻.70例耐药组患儿与62例控制组患儿及62例健康对照相比较,各组CC基因型、CT基因型、TT基因型及等位基因频率差异均无统计学意义.多因素Logistic回归分析显示,MDR1C3435T各基因型与癫(癎)耐药无相关性.结论 儿童癫(癎)患儿正规治疗6个月后仍不能控制发作者认为其为难治性癫(癎)(平均至少1次/月,>2种药物无效),多种AEDs治疗仍有其必要性,未发现汉族儿童C3435T基因多态性与癫(癎)耐药的相关性.     

5，10-亚甲基四氢叶酸还原酶基因C677T多态性与先天性心脏病关系的Meta分析

摘要 目的 对5,10 亚甲基四氢叶酸还原酶（MTHFR）基因C677T多态性与先天性心脏病（CHD）的相关性研究进行Meta分析。方法 制定原始文献的纳入标准及检索策略,检索PubMed、EMBASE、Ovid、Springer、中国期刊全文数据库、维普中文科技期刊数据库、万方数据库和中国生物医学文献数据库（1994年1月至2009年1月）中的文献,收集MTHFR基因C677T多态性与CHD相关性的病例 对照研究,剔除不符合要求的文献,应用RevMan 4.2软件进行Meta分析,得出合并后的OR值及其95％CI。结果 共18篇文献符合纳入标准进入Meta分析。数据合并结果显示,子代MTHFR基因 677位点TT/CC和(TT+CT)/CC与CHD易感性有统计学意义,OR值（95％CI）分别为1.55（1.24~1.93）和1.23（1.06~1.42）,P<0.05;子代MTHFR基因677位点CT/CC与CHD易感性无统计学意义,OR值（95％CI）为1.15（0.99~1.34）,P>0.05。父亲MTHFR基因677位点TT/CC和(TT+CT)/CC与子代CHD的易感性有统计学意义,OR值（95％CI）分别为1.84（1.23~2.74）和1.33（1.04~1.71）,P<0.05;父亲MTHFR基因677位点CT/CC与子代CHD易感性无统计学意义,OR值（95％CI）为1.25（0.96~1.62）,P>0.05 。母亲MTHFR基因677位点TT/CC、CT/CC和(TT+CT)/CC与子代CHD易感性均无统计学意义,OR值（95％CI）分别为1.20（0.92~1.56）、1.03（0.86~1.24）和1.07（0.90~1.27）,P均>0.05。传递不平衡分析未发现在CHD核心家系的MTHFR基因677位点存在突变的传递不平衡现象,OR值为0.90（95％CI：0.79~1.12）,P>0.05。结论 子代MTHFR基因677位点TT和TT+CT为CHD的危险因素之一;父亲MTHFR基因677位点TT和TT+CT是子代CHD的危险因素之一;母亲MTHFR基因677位点多态性与子代CHD的发生无关。     

急性淋巴细胞白血病患儿亚甲基四氢叶酸还原酶基因多态性与大剂量甲氨蝶呤不良反应的相关性

目的探讨急性淋巴细胞白血病(ALL)患儿亚甲基四氢叶酸还原酶(MTHFR)基因677位点多态性与大剂量甲氨蝶呤(HDMTX)体内排泄及不良反应的相关性。方法 2008年3月-2010年2月在本院儿科中心和血液内科住院的完全缓解并接受HDMTX治疗的40例ALL患儿,在接受HDMTX治疗前应用PCR-限制性酶切片段长度多态性(RFLP)技术检测MTHFR基因C677T多态性,在HDMTX静脉输注开始后24 h、48 h应用荧光偏振免疫法(FPIA)测定其血浆MTX水平,密切观察ALL患儿HDMTX化疗后的不良反应,对化疗不良反应进行分级。对MTHFR677的基因多态性与MTX不良反应及HDMTX 48 h的MTX水平(MTX-48 h)的相关性进行分析。结果在有HDMTX相关不良反应的ALL患儿中,肝损害和骨髓抑制发生率最高。MTHFR C677T有肝脏损害的基因型分布频率由低到高为CC型40.0%,TT型60.0%,CT型80.0%,CT基因型者肝脏损害发生的风险是CC基因型者的6倍(OR=6.00,95%CI:1.05～34.32,P=0.044);677CT+TT基因型者肝脏损害发生的风险是CC基因型者的4.13倍(OR=4.13,95%CI:1.02～16.67,P=0.047)。MTHFR C677T基因型与骨髓抑制无明显相关性。携有MTHFR突变基因型(CT+TT)患者的48 hMTX血药质量浓度明显高于携带MTHFR野生型基因CC者(P=0.006)。结论 MTHFR 677位基因型可作为ALL患儿HDMTX化疗不良反应和药物体内排泄的有效预测指标。     

白介素-4基因C-33T多态性与呼吸道合胞病毒毛细支气管炎的相关性

目的 研究白介素-4(IL-4)基因C-33T与呼吸道合胞病毒(RSV)毛细支气管炎的易感性、病情严重程度的关系及对血清总IgE和鼻咽分泌物(NPS)IL-4水平的影响.方法 采用聚合酶链-限制性片段长度多态法(PCR-RFLP)检测130例RSV毛细支气管炎患儿和108例对照组儿童IL-4/C-33T位点多态性,分别用化学发光法和酶联免疫分析法,检测RSV毛细支气管炎患儿血清总IgE和NPs中IL-4水平.结果 两组IL-4启动子区C-33T位点均可见TT、CT和CC 3种基因型,其中病例组,TT、CT和CC基因型频率分别为66.9%、26.9%和6.2%,对照组分别为69.4%、26.9%和3.7%,两组差异无统计学意义(X2=0.758,P>0.05);病例组T、C等位基因频率分别为80.3%、19.7%,对照组分别为82.9%、17.1%,两组差异亦无统计学意义(X2=0.073,P>0.05;OR=0.847,P>0.05).病例组三种基因型间NPS中IL-4及血清总IgE水平差异均无统计学意义(H=0.103,F=0.529,P均>0.05);三种基因型频率在轻度组和中重度组间的差异亦无统计学意义(X2=0.825,P>0.05).结论 温州地区儿童存在IL-4/C-33T位点的多态性,但未发现其与RSV毛细支气管炎存在关联.     

MTHFR、TS联合作用与ALL患儿HD-MTX化疗毒副作用的关系

目的：探讨 MTHFR、TS基因多态性联合作用对ALL患儿HD-MTX化疗后不良反应的影响,以及与MTX血药浓度变化之间的关系;分析MTHFR、TS基因多态性联合作用在个体化治疗及疾病防治中的作用。方法 ALL患儿73例,提取其基因组DNA,PCR扩增后测序鉴定MTHFR C677T、MTHFR A1298C、TS 5’-UTR的基因型。观察所有ALL患儿HD-MTX化疗后的毒副作用,并监测MTX血药浓度。以Logistic 回归分析基因多态性与化疗毒副作用的危险度;采用Fisher精确概率法比较 HD-MTX 化疗后 MTHFR C677T、MTHFR A1298C、TS 的不同基因型之间42～48 h MTX血药浓度的差异,以P＜0.05为差异有显著性。结果（1）MTHFR677 CT／TT合并1298 AC／CC基因型者,其血红蛋白降低发生的风险下降了2.9倍,而黏膜损害发生的风险则增加了4.3倍,但差异均无显著性。（2）MTHFR1298 AC／CC合并TS 3R／3R基因型者,其发生黏膜损害的风险增加了5.4倍,差异有显著性（χ2＝4.911,P＝0.027）。（3）MTHFR677 CT／TT合并TS 3 R／3R基因型与HD-MTX化疗毒副作用的发生无关。（4）MTHFR677 CT／TT＋MTHFR1298 AC／CC＋TS 3 R／3 R基因型者,其黏膜损害发生的风险增加了7.5倍,且差异有显著性（χ2＝5.295,P ＝0.021）。结论 TS和MTHFRC677T基因多态性可与ALL患儿HD-MTX化疗后黏膜损害的发生有关。     

儿童癫癎对药物反应性与多药耐药基因MDR1C3435T多态性的相关性研究

目的:探讨汉族癫癎患儿MDR1基因单核苷酸多态性（C3435T）与对抗癫癎药物反应的相关性。方法：214例癫癎患儿根据对抗癫癎药物的反应性分为耐药组和对药物反应良好组,提取外周血基因组DNA,用PCR-RFLP的方法即多聚合酶链反应（PCR）扩增后继以限制性内切酶片断长度多态性（RFLP）分析,对不同药物反应性与基因型频率、等位基因频率结果进行分析。结果：214例可明确分型的病例中,对药物反应良好的有164例,耐药的有50例 。两组病例的等位基因频率比较和基因型频率相比较,均未发现差异有显著性。结论：该研究未能反映汉族儿童C3435T基因多态性与癫癎病例对药物反应之间的相关性。［中国当代儿科杂志,2007,9（1）：11-14］     

The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis

Many pharmacogenomic predictors of drug response are now available, and include both drug metabolism-disposition factors and drug targets. Information on statistical approaches to analyzing large clinical data sets in relation to genetic polymorphisms is limited. The objective of this study was to evaluate whether logistic regression could identify pharmacogenomic predictors of outcome in a large data set in a complex transplant patient population. Seventy pediatric heart transplant patients were studied. Patients were followed for at least 1 yr post-transplantation as outpatients, and weaned from corticosteroids if clinically appropriate. Logistic regression analysis was used to identify the predictors of steroid dependency. The dependent variable was the presence or absence of steroid therapy at 1 yr post-transplantation. The independent variables were the patients' transplant age, gender, MDR1 C3435T and G2677T, CYP3A53B and cytokine polymorphisms. By chi-square test for the MDR1 C3435T polymorphism, 12 of 18 (67%) patients in the CC group were still on prednisone, whereas only 18 of 47 (38%) of the CT/TT group were still receiving prednisone (p = 0.04). For the IL-10 groups, two of 15 patients with the high producer genotype (13.3%) remained on prednisone, in comparison with 16 of 28 patients with the intermediate producer genotype (57.1%) and 15 of 26 patients with the low producer genotype (57.7%, p = 0.01). Logistic regression analysis confirmed MDR1 C3435T (p = 0.021), and IL-10 polymorphisms (intermediate producer genotype p = 0.015; low producer genotype p = 0.013) as independent risk factors for steroid dependency at 1 yr after transplantation. This approach identifies pharmacogenomic factors, which can be studied more extensively in larger data sets, and used in prospective studies to individualize immunosuppressive therapy following solid organ transplantation.     

Maternal Medication Use,Fetal 3435 C>T Polymorphism of the ABCB1 Gene,and Risk of Isolated Septal Defects in a Han Chinese Population

The fundamental etiology of the majority of nonsyndromic congenital heart defects is commonly believed to involve the interaction of multiple environmental and genetic factors. This study aimed to explore the joint effects of fetal 3435 C>T polymorphism in the ABCB1 gene and maternal medication use on the risk of septal defects in a Han Chinese population. An age- and gender-matched case–control study involving 265 pairs was conducted from March 2012 to September 2013. Information on maternal periconceptional medication use was obtained through questionnaires. The genotyping of 3435 C>T polymorphism was performed by sequencing. Logistic regression analysis was performed to assess the joint effects of ABCB1 gene 3435 C>T polymorphism and maternal medication use on the risk of septal defects. Use of maternal medication periconceptionally was significantly associated with an increased risk of septal defects [adjusted odds ratio (OR) 2.133; 95 % confidence interval (CI) 1.361–3.444; P = 0.001)]. The genotype distributions of 3435 C>T polymorphism differed significantly between cases and control subjects (P < 0.001). Meanwhile, more patients were carriers of the ABCB1 CC/CT genotypes, which were significantly associated with an increased risk of septal defects (OR 2.414; 95 % CI 1.418–4.110; P = 0.001). Children who carry the CC/CT genotype and have been exposed periconceptionally to medication have an almost fourfold increased risk of having septal defects than nonexposed children with the TT genotype (adjusted OR 3.932; 95 % CI 1.708–9.051), particularly perimembranous ventricular septal defects (VSD) (adjusted OR 4.070; 95 % CI 1.570–10.552). In conclusion, fetal 3435 C>T polymorphism in the ABCB1 gene increases the risk for isolated septal defects in the presence of maternal medication use periconceptionally, particularly for perimembranous VSD.     

1173C>T Polymorphism in VKORC1 Modulates the Required Warfarin Dose

The response to warfarin is highly variable among individuals and such variability is likely to have some genetic basis. We evaluted the effect of VKORC1 polymorphisms on warfarin response among Japanese, taking advantage of its unique population structure in which CYP2C9 *2 and *3 alleles are relatively rare. Thirty-one patients (12–34 years old; median, 22) on warfarin were recruited from a pediatric cardiology clinic. Genotyping of the C>T polymorphism at position 1173 in intron 1 of VKORC1 revealed that 26 patients (84%) were T/T homozygotes at nucleotide 1173, whereas 5 (16%) were C/T heterozygotes. Complete linkage disequilibrium was observed between the 1173C > T polymorphism and another polymorphism, the 3730G > A, in the 3′ untranslated region. The C/T heterozyogtes at the 1173C > T polymorphism tended to require more warfarin than the T/T homozygotes, when adjusted for international normalized ratio (p = 0.003). Both the 1173C > T polymorphism and the 3730G > A polymorphism are likely to be inert from a functional standpoint. Rather, based on the complete linkage disequilibrium between 1173C > T and 3730G > A polymorphisms, we suspect that the actual change that defines the relative resistance to warfarin may be present in the proximity of these two polymorphisms.     

The CBLB gene and Graves' disease in children

The CBLB gene functions as a negative regulator of autoimmunity. Impairment of the Cbl-b signaling pathway may contribute to human autoimmune disease. dbSNP rs2305035 is a C/T polymorphism located in exon 10 of the CBLB gene. We report an association study of this polymorphism in children with Graves' disease. The patients were 158 unrelated children (125 girls) with Graves' disease, aged 9.8 +/- 3.3 years. The controls consisted of 237 adults without a history of autoimmune disease. The C allele and phenotype frequencies of patients and controls were 247 (78.2%) vs 356 (75.1%) (OR = 1.19, p >0.05) and 151 (95.6%) vs 221 (93.2%) (OR = 1.56, p >0.05), respectively. The allelic polymorphism in patients and controls with and without DRB1*09012 were also not significantly different. This study demonstrates that the C/T polymorphism in exon 10 of the CBLB gene is not associated with Graves' disease in children.     

新生儿高胆红素血症与有机阴离子转运体1B1 T521C/A388G多态性的相关性研究

目的 有机阴离子转运体1B1(OATP 1B1)跨膜转运体内非结合胆红素(UCB),其基因变异能显著影响体内胆红素水平.此课题即为研究OATP 1B1基因多态性与新生儿高胆红素血症的相关性.方法 用聚合酶链式反应-限制性片段长度多态性(PCR-RFLP)方法分析220例高胆红素血症新生儿及200名对照者OATP 1B1 T521/A388G基因型,观察基因突变频率及基因型分布、基因多态性与疾病的相关性及对患儿血清总胆红素、结合胆红素、非结合胆红素水平的影响.结果 在高胆红素血症新生儿中,OATP 1B1 T521C等位基因突变频率显著下降,仅为8.2%.野生型的患者比例要显著高于对照组中野生型个体比例,达到84.1%.携带C等位基因的个体患病风险下降(OR=0.530,95%CI=0.328～0.857).血清总胆红素、结合胆红素、非结合胆红素水平在OATP 1B1A388G野生型患者中最高,杂合子次之,突变纯合子最低.结论 OATP 1B1 T521C多态性在新生儿高胆红素血症患儿中存在明显差异,OATP 1B1 A388G多态性显著影响新生儿高胆红素血症患儿血清胆红素水平.OATP 1B1 T521C/A388G是和新生儿高胆红素血症相关的重要基因多态位点.     

The promoter region of the CTLA4 gene is associated with type 1 diabetes mellitus

The CTLA4 (cytotoxic T lymphocyte associated antigen-4) gene encodes the T cell receptor involved in the control of T cell proliferation and mediates T cell apoptosis. C-T polymorphism is present at position -318 from the ATG start codon in the promoter region of the gene. We report a study on the polymorphism in 347 unrelated children with type 1 diabetes mellitus (DM) (age at diagnosis 7.2+/-3.8 years) and their 260 healthy siblings as controls. Genotype C/C conferred a risk of type 1 DM (RR = 2.02, 95% CI 1.32-3.10, pc = 0.0033). The gene frequency of the C allele was higher in patients (RR = 1.91, 95% CI 1.28-2.84, pc = 0.0026). The gene frequency and phenotype frequency of the T allele were negatively associated with type 1 DM (RR = 0.52, 95% CI 0.35-0.78, pc = 0.0026 and RR = 0.49, 95% CI 0.32-0.76, pc = 0.0022, respectively). The frequency of genotype C/T was lower in patients (RR = 0.50, 95% CI 0.32-0.78, pc = 0.0051). This study demonstrates that nucleotide -318 C-T polymorphism of the CTLA4 gene is associated with type 1 DM. The promoter allele -318 C confers a risk of type 1 DM but allele -318 T confers protection against this disease.     

肺泡表面活性物质蛋白B基因多态性与支气管肺发育不良易感性的关系

目的 了解肺泡表面活性物质蛋白B(SPB)-18A/C和SPB 1580C/T基因多态性与支气管肺发育不良(BPD)易感性的关系.方法 应用聚合酶链反应-限制性片段长度多态分析技术及基因测序技术检测57例BPD患儿及103例同胎龄无BPD早产儿的SPB-18及SPB 1580基因多态性,比较2组SPB-18及SPB 1580基因型和基因分布的差异.结果 1.SPB-18A/C基因型在BPD组与对照组AA、AC、CC基因型频率分别为14.0%、45.6%、40.4%和4.9%、31.1%、64.1%;A等位基因增加新生儿患BPD的风险:AC/CC与AA/CC 的OR值分别为2.3(95%CI 1.2~4.7,P=0.02)和4.7(95%CI 1.4~16.2,P=0.01);2.SPB 1580C/T基因型在对照组和BPD组TT、CT、TT分布分别为6.8%、45.6%、47.6%和12.3%、40.4%、47.4%,对照组和BPD组比较差异无统计学意义(χ2=1.50, P＞0.05).结论 中国武汉汉族人中SPB-18基因多态性是BPD的危险因素,基因型为AA者是BPD易感人群.SPB 1580 C/T基因多态性与BPD发病无明显相关性.     

全面性癫癎伴热性惊厥附加症家系GABRB2基因测序研究

目的对全面性癫伴热性惊厥附加症(GEFS )侯选基因GABRB2进行测序研究。方法设计GABRB2外显子-内含子交界处内含子引物,采用PCR直接测序法,对一GEFS 家系GABRB2编码区全部11个外显子进行测序分析。结果患儿GABRB2基因外显子2,mRNA第133个碱基发现一新的C/G多态性。结论该家系未发现GABRB2基因编码区的突变;所显示的mRNA的单个碱基多态性对以后其他癫家系的连锁分析及GABRB2 mRNA、基因功能研究均有重要意义。